These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 29051736)
21. The therapeutic potential of second and third generation CB Cinar R; Iyer MR; Kunos G Pharmacol Ther; 2020 Apr; 208():107477. PubMed ID: 31926199 [TBL] [Abstract][Full Text] [Related]
22. Pyrazole antagonists of the CB1 receptor with reduced brain penetration. Fulp A; Zhang Y; Bortoff K; Seltzman H; Snyder R; Wiethe R; Amato G; Maitra R Bioorg Med Chem; 2016 Mar; 24(5):1063-70. PubMed ID: 26827137 [TBL] [Abstract][Full Text] [Related]
23. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice. Chen B; Hu N Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810 [TBL] [Abstract][Full Text] [Related]
24. Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications. Nagappan A; Shin J; Jung MH Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035653 [TBL] [Abstract][Full Text] [Related]
25. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Perwitz N; Wenzel J; Wagner I; Büning J; Drenckhan M; Zarse K; Ristow M; Lilienthal W; Lehnert H; Klein J Diabetes Obes Metab; 2010 Feb; 12(2):158-66. PubMed ID: 19895638 [TBL] [Abstract][Full Text] [Related]
26. Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. Seltzman HH; Shiner C; Hirt EE; Gilliam AF; Thomas BF; Maitra R; Snyder R; Black SL; Patel PR; Mulpuri Y; Spigelman I J Med Chem; 2016 Aug; 59(16):7525-43. PubMed ID: 27482723 [TBL] [Abstract][Full Text] [Related]
27. Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain. Zhang H; Lund DM; Ciccone HA; Staatz WD; Ibrahim MM; Largent-Milnes TM; Seltzman HH; Spigelman I; Vanderah TW Pain; 2018 Sep; 159(9):1814-1823. PubMed ID: 29781960 [TBL] [Abstract][Full Text] [Related]
28. MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future. Simon V; Cota D Eur J Endocrinol; 2017 Jun; 176(6):R309-R324. PubMed ID: 28246151 [TBL] [Abstract][Full Text] [Related]
29. Peripheral CB1R as a modulator of metabolic inflammation. Han JH; Kim W FASEB J; 2021 Apr; 35(4):e21232. PubMed ID: 33715173 [TBL] [Abstract][Full Text] [Related]
30. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. Pavon FJ; Bilbao A; Hernández-Folgado L; Cippitelli A; Jagerovic N; Abellán G; Rodríguez-Franco MA; Serrano A; Macias M; Gómez R; Navarro M; Goya P; Rodríguez de Fonseca F Neuropharmacology; 2006 Aug; 51(2):358-66. PubMed ID: 16750544 [TBL] [Abstract][Full Text] [Related]
31. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats. Lazzari P; Serra V; Marcello S; Pira M; Mastinu A Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074 [TBL] [Abstract][Full Text] [Related]
32. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists. Janero DR Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400 [TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB Iyer MR; Cinar R; Katz A; Gao M; Erdelyi K; Jourdan T; Coffey NJ; Pacher P; Kunos G J Med Chem; 2017 Feb; 60(3):1126-1141. PubMed ID: 28085283 [TBL] [Abstract][Full Text] [Related]
35. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development. Nguyen T; Thomas BF; Zhang Y Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863 [TBL] [Abstract][Full Text] [Related]